As a 1p/19q codeletion, MGMT promoter methylation and IDH1 mutation is an important marker for the prognostic evaluation of glioma patients, and we investigated expression of HIC2 and this clinicopathologic feature. The gene discussed is MGMT; the disease is glioma.